DAY ONE | MONDAY, APRIL 29
8:00 REGISTRATION & WELCOME COFFEE
8:50 CHAIRPERSON’S OPENING REMARKS
Stephen Douthwaite, Partner, Head of Client Services, ALPHABIOCOM
9:00 – 10:30 OPTIMIZATION STRATEGIES FOR PRODUCT PRE-LAUNCH TIMELINE MANAGEMENT
Deliberate approaches to pre-launch planning activities with strong attention to timeline objectives set apart the success of a product launch. A keen understanding of when to develop pre-launch materials, how to define engagement activities, and best practices for structuring field and internal teams are critical considerations when building a product’s pre-launch agenda. The structured alignment of these activities by medical affairs executives are the foundation for successful launch outcomes and medical affairs teams are constantly exploring past successes and lessons learned to ensure current prelaunch timelines are constructed to generate positive launch results.
9:00 LAUNCH TIMELINE PLANNING FOR UNMET NEED
- Assigning pre-launch activities specific unmet need timelines
- Alternate options for approaching strategies with limited resources
- Determining appropriate time for disease state awareness education
Andrea Hafeman, Director, Medical Affairs, PORTOLA PHARMACEUTICALS
9:30 LAUNCH TIMELINE PLANNING FOR ESTABLISHED MARKETS
- Maintaining efficiency while developing pre-launch activities
- Considerations for timeline practices in competitive markets
- Establishing ideal points to facilitate engagement activities
Karin Tollefson, Vice President Medical Affairs, NEKTAR THERAPEUTICS
10:00 TIMELINE MANAGEMENT SMALL GROUP DISCUSSIONS
Facilitated discussions will provide attendees with an opportunity to exchange insight and strategies associated with aligning pre-launch activities in line with ideal timeline management.
- GROUP 1: RARE DISEASE
Andrea Kho, ABBVIE
- GROUP 2: UNMET NEED
Andrea Hafeman, PORTOLA PHARMACEUTICALS
10:30 COFFEE AND NETWORKING BREAK
11:00 TOP 7 REASONS TO HAVE A CLINICAL TRIAL LIAISON TEAM
The roles of Medical Science Liaisons (MSLs) have evolved, as have their metrics and perceived value from both internal and external customers. We will explore their increasing involvement in clinical research and trial efficiency. As they are more engaged, how does the MSL need to evolve, and how does Medical Affairs collaborate with Research and Development and Clinical Operations? A case study of the deployment of MSLs as Clinical Trial Liaisons (CTLs) will be presented. Increasing access to these field medical teams through the newest cutting-edge technology will also be highlighted.
Michael Banks, Managing Director, BESTMSLs
11:45 PANEL DISCUSSION: RESOURCE ALLOCATION ACROSS PRE-LAUNCH OPERATIONS
To efficiently distribute resources throughout all pre-launch operations, medical affairs professionals must determine the scope of required support and the impact of allocation methods throughout the pre-launch process. Executives are called to share reasoning behind strategic decision making for field and internal teams, methods to adapt distribution efforts in changing launch environments, and best practices for prioritization. Skillfully aligning appropriate resources throughout pre-launch procedures ensure strategies are best conducted for product launch objectives.
- Strategic thought processes for allocation
- Determining necessary levels of manpower
- Adapting resource distribution to changing demands
MODERATOR: Michael Banks, BESTMSLs
Ruthann Thomas, SHIONOGI
Brandi Howard, EVOFEM BIOSCIENCES
Jo Ann Kerwin, EISAI, INC.
Dean Najarian, JANSSEN
12:30 LUNCHEON FOR ALL ATTENDEES
1:30 DETERMINING PRE-LAUNCH STRATEGIES BY PIPELINE DEVELOPMENT
Designing pre-launch strategies with the most optimal level of medical affairs involvement varies depending where an organization is positioned regarding pipeline development. Establishing pre-launch activities with specific focus to pipeline development allows medical affairs teams to directly angle approaches that best apply to organizational need. Divided by level of products in pipeline, medical affairs professionals are called to exchange methods to determine when to involve medical affairs, benefits and drawbacks of early medical affairs involvement, and pre-launch activities specific to similar pipelines.
- GROUP 1: 0 – 5 PRODUCTS
Edmund Doherty, REATA PHARMACEUTICALS
- GROUP 2: 5 – 10 PRODUCTS
Valerie Dodane, GSK
- GROUP 3: 10 – 15 + PRODUCTS
Michael Cobas Meyer, ELI LILLY AND COMPANY
2:15 HAYMARKET MEDICAL NETWORK CASE STUDY PRESENTATION
3:00 COFFEE AND NETWORKING BREAK
3:30 KOL MAPPING: INNOVATIVE APPROACHES TO RELATIONSHIP DEVELOPMENT
Cultivating collaborative relationships with impactful KOLs has a great impact on industry awareness of upcoming products and manufacturers are extending outreach strategies to target opinion leaders beyond traditional experts. Increasing the scope of KOLs outside frequently published professionals increases the impact of product awareness and in turn further strengthens the pre-launch process. It is critical for medical affairs teams to proactively engage in comprehensive KOL mapping processes to discover and develop key relationships with opinion leaders early in a product’s lifecycle to ensure maximum KOL influence.
- Balancing the inclusion of published and un-published KOLs
- Optimal timeline for KOL mapping strategies development
- Outreach tactics to engage with innovative KOLs
Daniel Snyder, PhD, Head of Medical Affairs, Therapeutics, REVANCE THERAPEUTICS
4:15 KOL MAPPING SMALL GROUP DISCUSSIONS
Facilitated discussions will provide participants with an opportunity to delve into unique KOL mapping challenges associated with certain market segments to ensure optimal collaboration with key industry opinion leaders.
- GROUP ONE: ESTABLISHED MARKET
Daniel Snyder, REVANCE THERAPEUTICS
- GROUP TWO: RARE DISEASE MARKET
5:00 COCKTAIL RECEPTION FOR ALL CONFERENCE PARTICIPANTS
SPONSORED BY: HAYMARKET MEDICAL NETWORK
6:00 END OF DAY ONE CONFERENCE